Corticosteroid Uptake For COVID-19 after Publication of RECOVERY: A Difference in Difference Model

Kearney, C.; Lesieur, M.; Bosch, Nicholas A; Walkey, Allan J.

doi:10.1513/annalsats.202208-715rl

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there remain questions about optimal corticosteroid choice and dose, dexamethasone has become standard of care for hospitalized patients with severe or critical COVID-19 [ 25 ]. The corticosteroid arc within the COVID-19 saga holds multiple important lessons, including the potential fallibility of extrapolation to a novel virus even from highly related known pathogens and the humility required to swiftly reverse prior recommendations in the face of new, high-quality data that contradicts prior consensus.…”

Section: Corticosteroids For Covid-19mentioning

confidence: 99%

The Penn Medicine COVID-19 Therapeutics Committee—Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency

Anesi,

Degnan,

Dutcher

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

The Penn Medicine COVID-19 Therapeutics Committee—an inter-specialty, clinician-pharmacist, and specialist–front line primary care collaboration—has served as a forum for rapid evidence review and the production of dynamic practice recommendations during the three-year COVID-19 public health emergency. We describe the process by which the Committee went about its work and how it navigated specific challenging scenarios. Our target audiences are clinicians, hospital leaders, public health officials, and researchers invested in preparedness for inevitable future threats. Our objectives are to discuss the logistics and challenges of forming an effective committee, undertaking a rapid evidence review process, aligning evidence-based guidelines with operational realities, and iteratively revising recommendations in response to changing pandemic data. We specifically discuss: the arc of evidence for corticosteroids; the noble beginnings and dangerous misinformation end of hydroxychloroquine and ivermectin; monoclonal antibodies and emerging viral variants; and patient screening and safety processes for tocilizumab, baricitinib, and nirmatrelvir-ritonavir.

show abstract

Section: Corticosteroids For Covid-19mentioning

confidence: 99%